Back to Journals » Therapeutics and Clinical Risk Management » Volume 8

Aripiprazole in the acute and maintenance phase of bipolar I disorder

Authors Zupancic M, Gonzalez

Received 17 November 2011

Accepted for publication 30 November 2011

Published 12 January 2012 Volume 2012:8 Pages 1—6

DOI https://doi.org/10.2147/TCRM.S22579

Review by Single-blind

Peer reviewer comments 2


Melanie Zupancic1, Misty L Gonzalez2,3
1Southern Illinois University School of Medicine, 2Division of Medicine Psychiatry, Southern Illinois University School of Medicine, 3Southern Illinois University Edwardsville School of Pharmacy, Southern Illinois University Edwardsville, Springfield, IL, USA

Abstract: Bipolar affective disorder is a disabling illness with substantial morbidity and many management challenges. Traditional mood stabilizers such as lithium, valproate, and carbamazepine are often inadequate in controlling symptoms both during the acute and maintenance phase of treatment. Aripiprazole is a second-generation antipsychotic with a unique mechanism of action. Evidence suggests that it is effective in acute manic and mixed states. There are limited data to suggest its efficacy as a maintenance agent. Future studies will be needed to better define the role of aripiprazole relative to other traditional pharmacologic agents.

Keywords: aripiprazole, bipolar disorder, acute treatment, maintenance treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]